Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lipid Profiling of Children With FH

Atherosclerosis; ePub 2017 Sep 20; Christensen, et al

Children with familial hypercholesterolemia (FH) had higher atherogenic ApoB-containing lipoproteins and lipid fractions, as well as alterations in HDL sub fractions that suggest impaired reverse cholesterol transport, when compared to healthy children, a recent study found. The cross-sectional study measured plasma metabolites in children with FH (n=47) and in healthy children (n=57) using a high-throughput nuclear magnetic resonance (NMR) spectroscopy platform, and compared the differences between FH and healthy children. Researchers found:

  • Both statin treated (n=17) and non-statin treated FH children (n=30) had higher levels of atherogenic ApoB-containing lipoproteins and lipids, and lipid fractions in lipoprotein subclasses, compared to healthy children.
  • Children with FH displayed alterations in HDL particle concentration and lipid content vs healthy children.
  • Global alterations roughly displayed the opposite effect of statin treatment in adults.
  • NMR-based lipidomics may improve risk classification and guide treatment intensity.

Christensen JJ, Ulven SM, Retterstøl K, et al. Comprehensive lipid and metabolic profiling of children with and without familial hypercholesterolemia: A cross-sectional study. [Published online ahead of print September 20, 2017]. doi:10.1016/j.atherosclerosis.2017.09.021.

This Week's Must Reads

AHA Statement on Noncardiac Complications in CHD, Circulation; ePub 2017 Oct 9; Lui, Saidi, et al

AHA Updates Practice Standards for ECG Monitoring, Circulation; ePub 2017 Oct 3; Sandau, et al

Intensive SBP Lowering in Patients with Low DBP, Circulation; ePub 2017 Oct 11; Beddhu, et al

BP Targets for Patients with Hypertension & CVD, Cochrane; 2017 Oct 11; Saiz, Gorricho, et al

Thoracic Extra-Coronary Calcification & Stroke Risk, Atherosclerosis; ePub 2017 Oct 7; Kianoush, et al

Must Reads in Hypercholesterolemia

LDL-C Reduction with Evolocumab & PCSK9 Inhibitors, J Am Heart Assoc; ePub 2017 Oct 2; Toth, et al

Efficacy of Evolocumab in Patients with HeFH, J Clin Lipidol; ePub 2017 Sep 22; Hovingh, et al

Patient Access to PCSK9 Inhibitor Therapy, JAMA Cardiol; ePub 2017 Sep 27; Navar, et al

LDL Pattern & Mortality After Myocardial Infarction, J Clin Lipidol; ePub 2017 Oct 3; Pokharel, et al

Increased Risk of HF and AF in Patients With FH, Atherosclerosis; 2017 Nov; Hovland, Mundal, et al